Intercept Pharmaceuticals Reports 2015 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Wedbush Cuts PT on Intercept Pharma (ICPT) to $423, Remains Bullish
February 24, 2016 8:17 AM ESTWedbush analyst, Liana Moussatos, reiterated her Outperform rating on shares of Intercept Pharma (NASDAQ: ICPT) and thinks there will be a buying opportunity ahead of the release of AdComm briefing documents on April 7th. Acquisition value drops to $423 from $493 as expectations for the NASH launch are pushed to late19 from H1:18.
Intercept reported Q4 / FY revenues of $0.45MM / $2.78MM on GAAP EPS of $(3.62) / $(9.56) vs. consensus revenues est. of... More
Intercept Pharma (ICPT) Misses Q4 EPS Views
February 23, 2016 7:07 AM ESTIntercept Pharma (NASDAQ: ICPT) reported Q4 EPS of ($3.62), $0.47 worse than the analyst estimate of ($3.15). Revenue for the quarter came in at $447 thousand versus the consensus estimate of $720 thousand.
Planned 2016 Milestones
PBC ProgramScheduled FDA Advisory... More